Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes

Status: ACTIVE_NOT_RECRUITING | Phase: PHASE2/PHASE3 Condition(s): Breast Cancer Intervention(s): Raloxifene - Usual (DRUG), Raloxifene - Study (DRUG) Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Detailed: The usual approach group, after breast tissue biopsy, 300 double blind random group separated BC-LCIS patients currently used the Chemotherapy on Generic-1 - raloxifene hydrochloride tablet, 60 mg daily, it will try to look for the relationship between the Raloxifene therapeutic efficacy and the ER SNP Genotyping, after blood draw, to look for the relationship between the Raloxifene therapeutic safety and the UGT SNP Genotyping, based on Oxford precisely sequencing drug targets' genes. The study approach group, after breast tissue biopsy, 300 double blind random group separated BC-LCIS patients currently used the Chemotherapy on Generic-2 - Raloxifene tablet, 60 mg daily, it will try to look for the relationship between the Raloxifene therapeutic efficacy and the ER SNP Genotyping, after Primary Outcome(s): Measure and Report Raloxifene oncology drug target ER SNP Genotypes which are effectiveness associated.; Measure and Report Raloxifene oncology drug target UGT SNP Genotypes which are risk associated. Enrollment: 600 (ESTIMATED) Lead Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Start: 2025-06-21 | Primary Completion: 2026-12-18